Cynthia E. Dunbar

Dec 8, 2024 | healio.com | Josh Friedman |Mark Leiser |Cynthia E. Dunbar

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Most children with relapsed or refractory B-lineage acute lymphoblastic leukemia achieved complete remission with bicistronic CAR-T. Nearly half of participants had grade 3 or 4 cytokine release syndrome.

Dec 8, 2024 | healio.com | Josh Friedman |Mindy Valcarcel |Cynthia E. Dunbar

Cynthia E. Dunbar, MD Despite recent FDA approvals of two gene therapies for severe sickle cell disease, potential safety concerns persist. Lentiviral gene addition carries a potential risk for leukemia due to insertional genotoxicity. CRISPR/Cas gene editing induces double-stranded DNA breaks that can be toxic to hematopoietic stem cells. Thus, there is intense interest in novel targeted approaches not predicted to share these risks.

Jan 25, 2024 | healio.com | Drew Amorosi |Mindy Valcarcel |Cynthia E. Dunbar |James Berenson

You've successfully added Hematology Oncology: Myeloma to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Patients treated in real-world settings had significantly worse survival outcomes for six of seven regimens evaluated.

Oct 12, 2023 | nature.com | Naoya Uchida |Selami Demirci |Xiaolin Wu |Cynthia E. Dunbar |Robert E. Donahue

AbstractHematopoietic stem cell (HSC) gene therapy has curative potential; however, its use is limited by the morbidity and mortality associated with current chemotherapy-based conditioning. Targeted conditioning using antibody-drug conjugates (ADC) holds promise for reduced toxicity in HSC gene therapy. Here we test the ability of an antibody-drug conjugate targeting CD117 (CD117-ADC) to enable engraftment in a non-human primate lentiviral gene therapy model of hemoglobinopathies.